Navigation Links
Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis

NEW ORLEANS--(BUSINESS WIRE)--Mar 26, 2007 - Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting of the American College of Cardiology.

In the Lipitor arm of the ILLUSTRATE and RADIANCE 1 trials, patients took an average Lipitor dose of 23 mg and 56 mg respectively and experienced halting of the progression of atherosclerosis. In the ILLUSTRATE trial, treatment with Lipitor resulted in plaque regression in the most diseased part of the coronary artery. In contrast in the Lipitor arm of RADIANCE 2 patients took a low average Lipitor dose of 13 mg and progression of atherosclerosis was observed.

"From a clinical perspective, what is remarkable in these studies is that Lipitor was able to stop the progression of disease, including the most difficult to treat FH patients studied in RADIANCE 1," said Professor John Kastelein, lead investigator for two of the trials, and professor of medicine and chairman of vascular medicine at the Academic Medical Center in Amsterdam. "These trials build on the effects seen with Lipitor in numerous imaging trials."

Lipitor is the only statin to have been studied in head-to-head imaging trials. In the ASAP and ARBITER trials, which measured changes in cIMT, high-risk patients who took Lipitor 80 mg experienced regression in atherosclerosis compared with patients who took other statins. In the REVERSAL trial, Lipitor patients experienced a halting of plaque progression compared with pravastatin, and Lipitor patients experienced a significant reduction in the plaque volume in the most diseased segments compa
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
2. Repligen Reports Positive Phase 2 Clinical Trial Results of Secretin for MRI Imaging of the Pancreas
3. Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimers Disease Presented at AD/PD Meeting
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
6. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
7. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
8. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
9. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
10. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
11. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... EAST SETAUKET, N.Y., Aug. 12 Lixte,Biotechnology Holdings, ... had filed a patent application for the use ... brain tumors as potential treatments for,neurodegenerative diseases including ... Kovach, President and CEO of Lixte, said, "Lixte ...
... DIEGO, Aug. 12 MabVax Therapeutics, Inc., ... focused,on the development and commercialization of novel ... the completion of two separate,licensing agreements with ... Cancer Research (SKI)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO ...
Cached Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research 2
(Date:4/17/2014)... Hospital Pediatrician-in-Chief Jon McCullers, MD, was recently invited ... of Nature Reviews Microbiology , one of ... a world-renowned infectious disease specialist, and chair of ... Tennessee Health Science Center, analyzed the epidemiology and ... 1968 pandemics, as well as more recent 2009 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... Retardation -, PHILADELPHIA, Oct. 9 When ... ring before birth, they may,disrupt normal development and ... Children,s Hospital of Philadelphia will be investigating,one such ... Ring Chromosome,20 Foundation., Ring chromosome 20 syndrome, ...
... 9 House Republican Whip Roy,Blunt (Mo.) issued ... Clyburn (D-S.C.) yesterday suggested on CNN that Democrats ... the president,s veto of the,SCHIP bill:, "Yesterday, ... be,hard-pressed to override the president,s veto of a ...
... Quebec City, October 9, 2007People who experience chronic job ... of suffering from a second one, reports a research ... October 10 issue of the Journal of the American ... clearly demonstrate the risks associated with job strain for ...
... Oct. 9 Recent studies by Best,Practices, LLC ... 34 R&D,FTE,s per Quality FTE in Pharmaceutical companies. ... employees to effectively use a,Risk-Based Approach. Does your ... structure for Quality Assurance in R&D? What tools,are ...
... WASHINGTON, Oct. 9 The following was released,today by ... EDT, MR. TENPAS: Good morning. I am ... and Natural Resources Division here at the,Department of ... EPA,s,assistant administrator for Enforcement and Compliance Assurance., ...
... to boost abstinence, study finds , , TUESDAY, Oct. 9 ... seizures could be added to the short list of ... new study suggests. , The drug topiramate proved measurably ... from heavy drinking, the study authors said. , "Not ...
Cached Medicine News:Health News:Grant Supports Study of Abnormal Ring-Shaped Chromosomes 2Health News:Chronic job strain doubles the risk of a second heart attack 2Health News:Best Practice Database: Complimentary Excerpt of Pharma Quality Assurance Toolkit Available from Best Practices, LLC 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 2Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 3Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 4Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 5Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 6Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 7Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 8Health News:Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power 9Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 2Health News:Epilepsy Drug Holds Promise as Treatment for Alcoholism 3
Stab incision blades color coded for simple and accurate identification...
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
... has two perforations which enable ... various single or bilateral configurations ... drape has two perforations which ... to various single or bilateral ...
30, 6.0mm from end...
Medicine Products: